Dr. Isaacson says research has shown the drug, manufactured by Elli Lilly, has shown to help clear amyloid plaques, clumps of protein thought to disrupt cell function, from the brain.
The Food and Drug Administration approved a new Alzheimer's drug that has shown to halt progressive memory loss in people who are in the earliest stage of disease.
"Thirty-five percent. That buys a lot of time. It's an exciting time to be a neurologist, it's a hopeful time to be a patient with the earliest symptoms of Alzheimer's disease," says Dr. Richard Isaacson of the Institute for Neurodegenerative Diseases. Researchers also discovered the drug reduced participant's risk of progressing to the next stage of Alzheimer's by up 39%."There's no magic pill or IV – this is an IV medication. You have to do MRIs frequently to make sure that no side effects are developing," says Dr. Isaacson.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Hope in Alzheimer’s Fight: Researchers Identify Unique Early BiomarkerScience, Space and Technology News 2024
Read more »
FDA advisors strongly back new Alzheimer’s drug, despite risks and limitationsAdvisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.
Read more »
FDA advisors strongly back new Alzheimer’s drug, despite risks and limitationsAdvisors to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab.
Read more »
Here's an undervalued stock that can benefit from new Alzheimer's drugsThe Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.
Read more »
‘Reversing’ Alzheimer’s: Here are exercises to make the brain more resilientIn her new book “Reversing Alzheimer's: The New Tool Kit to Improve Cognition and Protect Brain Health,' Dr. Heather Sandison offers exercise tips to alleviate Alzheimer's symptoms.
Read more »
Independent FDA Panel Endorses New Alzheimer’s Disease TreatmentAn FDA advisory panel unanimously gave a green light on Monday to the Alzheimer’s disease treatment donanemab for use during early stages of the disease.
Read more »